RMD: Stock thesis & analysis

ResMed is a durable, high-ROE (24%) sleep-apnea device franchise with expanding operating margins (31%) and low leverage, but at 22.6x P/E and 37x P/FCF the valuation score (47/100) already prices in steady execution, leaving limited margin of safety for a medium-term entry. Smart-money confirmation is thin — two tracked funds with only partial persistence (Tier B) — which is a normal state for a large-cap device name outside the mandate of quant-style trackers rather than a red flag, so it neither adds nor subtracts from the thesis. Healthcare is currently sector-leading and macro is RISK_ON, a tailwind, but the late-cycle credit warning in HY spreads argues for selectivity, and recent realized results show high-conviction MT entries into this environment have stopped out; better to wait for a valuation reset or confirmed catalyst before sizing in.

Catalysts to watch

• Next quarterly earnings print (expected ~Oct 2026) — margin trajectory and mask/device volume trends
• Potential clarity on GLP-1 co-therapy data reducing device-substitution fear
• Additional 13F filings next quarter that could confirm or reverse fund persistence

Key risks

• Valuation embeds high expectations at 37x P/FCF, limiting margin of safety for new entries
• Smart-money coverage is thin — under-followed, only 2 tracked holders with partial persistence
• Insider sales in the past 30 days with no offsetting purchases
• GLP-1 drug class remains a durable overhang narrative on sleep-apnea device demand
• Late-cycle credit conditions (HY spreads flagged) argue for caution on paying up for growth multiples

What would change the view

• Stock breaks below $205.00 (below recent support and ~15% drawdown from current level)
• Operating margin falls below 27% for two consecutive quarters
• FCF margin compresses below 12% for two consecutive quarters, signaling deteriorating cash conversion at current valuation